Other Events ·
Can-Fite BioPharma Ltd. announced the submission of a Phase 2 clinical study protocol for Piclidenoson to treat Lowe…
CANFCan-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. announced the submission of a Phase 2 clinical study protocol for Piclidenoson to treat Lowe syndrome, a rare genetic disorder with no approved therapies. The open-label, single-center trial will enroll five adult patients at Bambino Gesù Children’s Hospital in Rome under the leadership of Prof. Francesco Emma. This initiative follows a collaboration agreement signed with Fondazione Telethon and is designed to support regulatory discussions regarding potential registration pathways. Can-Fite BioPharma Ltd. operates as a biotechnology company developing proprietary small molecule drugs for oncological, inflammatory, and rare genetic diseases.